General Information of Drug Combination (ID: DC9INVF)

Drug Combination Name
Carboplatin Vardenafil
Indication
Disease Entry Status REF
Glioma Phase 1 [1]
Component Drugs Carboplatin   DMG281S Vardenafil   DMTBGW8
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Carboplatin
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [2]
Carcinoma 2A00-2F9Z Approved [2]
Cholangiocarcinoma 2C12.10 Approved [2]
Cutaneous melanoma 2C30 Approved [2]
Epithelial ovarian cancer 2B5D Approved [2]
Fallopian tube neoplasm N.A. Approved [2]
Gastroesophageal junction adenocarcinoma 2B71 Approved [2]
Lung adenocarcinoma N.A. Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Ovarian cancer 2C73 Approved [3]
Ovarian disorder N.A. Approved [2]
Ovarian neoplasm N.A. Approved [2]
Ovarian serous cystadenocarcinoma N.A. Approved [2]
Small-cell lung cancer 2C25.Y Approved [2]
Lung large cell carcinoma N.A. Investigative [2]
Neuroblastoma 2D11.2 Investigative [2]
Carboplatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [6]
------------------------------------------------------------------------------------
Carboplatin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Carboplatin Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Metabolism [8]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Metabolism [8]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Metabolism [8]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Metabolism [8]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Metabolism [8]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Metabolism [8]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)
Indication(s) of Vardenafil
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Approved [4]
Erectile dysfunction HA01.1 Approved [5]
Vardenafil Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Binder [9]
------------------------------------------------------------------------------------
Vardenafil Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [11]
------------------------------------------------------------------------------------
Vardenafil Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A) OTT8Q1AP PDE5A_HUMAN Decreases Activity [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02279992) Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
2 Carboplatin FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
4 Vardenafil FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7320).
6 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
7 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
8 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
9 The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
10 Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
11 The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
12 Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin Drug Saf. 2005 May;4(3):531-40. doi: 10.1517/14740338.4.3.531.